Frag 176-191 — 5 mg

Frag 176-191 is a highly studied peptide fragment derived from the C-terminal end of human Growth Hormone (hGH). Unlike full-sequence GH, Frag 176-191 does not activate IGF-1 pathways—instead, research focuses on its role in metabolic enhancement, lipolysis, and fat-cell signaling.
It is explored for its ability to modulate adipocyte activity, increase fat oxidation, and support metabolic balance without the anabolic or glucose-modifying effects of GH.

Benefits

• Studied for increasing fat oxidation and lipolysis

• Does not trigger IGF-1 or full GH effects

• Explored for metabolic enhancement and weight-related research

• Interest in supporting stubborn-fat breakdown in research models

• Stable, targeted GH fragment with selective metabolic activity

What Researchers Look At

• Interaction with adipocyte receptors

• Non-IGF-1 metabolic activity pathways

• Comparative data vs. full growth hormone

• Lipolysis rates in preclinical fat-cell models

• Energy expenditure and mitochondrial signaling

Quick Specs

• Form: Lyophilized peptide

• Net per vial: 5 mg or 10 mg (depending on product selection)

• Purity: ≥99% (HPLC)

• Identity: MS-verified per COA

• Storage: 2–8 °C, protect from light

Identity Basics

• Sequence: Tyr-Lys-Pro-Val-Ser-Arg-Ile-Arg-Ala-Phe-Thr-Glu-Ser

• Formula / M.W.: C78H125N23O23 • ~1817.1 g/mol

• CAS: 221231-10-3

Selected Research (Copy/Paste Links)

• • https://pubmed.ncbi.nlm.nih.gov/25565050/

  • https://pubmed.ncbi.nlm.nih.gov/17624505/

  • https://pubmed.ncbi.nlm.nih.gov/18222440/

  • https://pubmed.ncbi.nlm.nih.gov/15498888/

⚠️ Disclaimer

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.